Dose-Intense Cisplatin-Based Neoadjuvant Chemotherapy Increases Survival in Advanced Cervical Cancer: An Up-to-Date Meta-Analysis.

Cancers (Basel) · 2022 · PMC8834199 · PMID 35159111

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

In 2020, the second meta-analysis only focused on stages IB2 and II cervical cancers and was thus limited to 5 studies, including 2 case–control studies and only 1275 patients, with a nonsignificant trend for a 40% reduction in the risk of death with neoadjuvant chemotherapy [ 50 ].

also in 5,406 other papers

did not reach statistical significanceno p-value reported

The RR of 0.84 was comparable in terms of PFS for the subgroup of studies with surgery as local treatment and receiving neoadjuvant chemotherapy, despite that it did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.